Skip to main content
. 2023 Sep 13;14:1237715. doi: 10.3389/fimmu.2023.1237715

Figure 1.

Figure 1

Binding, blocking, and signaling of CX3CR1 mAb. (A) FACS analysis of CX3CR1 mAb binding to 300 cells stably expressing mouse CX3CR1. (B) Agonist activity of CX3CL1 recombinant protein and of CX3CR1 mAb on CX3CR1-reporter CHO cells. (C) CX3CR1 mAb hybridoma supernatant blocking of CX3CL1-hFc (2 µg/ml) fusion protein binding to Jurkat cells stably expressing mouse CX3CR1. (D) Antagonistic activity of CX3CR1 mAb on CX3CL1 (500 ng/ml) signaling in CX3CR1-reporter CHO cells. (E) FACS analysis of CX3CR1 expression on CT26 from in vitro culture and from excised mouse tumor tissue. (F) CX3CR1 mAb (10 µg/ml) blockade of CT26 migration towards CX3CL1 (100 ng/ml) (n=3). Data representative of two independent experiments. Data as standard error of the mean, paired t-test, *p<0.05.